Apoptosis

Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)

Retrieved on: 
Thursday, February 1, 2024

BERWYN, PA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of a novel oncology therapeutic intended to improve the outcomes and quality of life for patients, today announced publication of positive data in the peer-reviewed Anti-Cancer Drugs in an article titled, “Antineoplastic Activity of GP-2250 In Vitro and in Mouse Xenograft Models.”1 The publication by Sofia et al. (2024) provided early research evidence that misetionamide exhibits a dose-dependent antineoplastic effect on both established cancer cell lines and xenograft models from patient tissues.2 Antineoplastic activity was tested in over 300 cancer cell lines using the OncoPanel® cytotoxicity assay and was further tested in eight human cancer xenograft models.

Key Points: 
  • Most notably in the ovarian tumor xenograft model, misetionamide produced a regression in the original tumor volume.
  • Concentrations for IC50 and EC50 were determined as was the concentration at which a 10-fold increase in apoptosis was induced.
  • In addition, misetionamide was also shown to induce a cancer cell cycle block that would inhibit tumor cells from replicating and thus inhibiting tumor growth.
  • “The results from these studies demonstrate that misetionamide has a broad mechanism of action which could be impactful in treating most cancers.

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Retrieved on: 
Monday, January 22, 2024

In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.

Key Points: 
  • In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.
  • Tolimidone is an activator of lyn kinase which has been shown to play a significant role in cell proliferation, differentiation, apoptosis, migration and metabolism.
  • We expect to report data from the in vivo LMD efficacy model by the end of the first quarter of 2024.
  • Certain statements in this shareholder letter may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States.

Eisai Aims to Advance Genitourinary Cancer Treatment with New Research at ASCO GU 2024

Retrieved on: 
Thursday, January 18, 2024

NUTLEY, N.J., Jan. 18, 2024 /PRNewswire/ --  Eisai announced today the presentation of research in renal cell carcinoma (RCC) during the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (#GU24) which is taking place in-person in San Francisco, California and online from January 25-27. Notable presentations include a rapid oral abstract session featuring subgroup analyses from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which evaluated lenvatinib (LENVIMA®), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus pembrolizumab (KEYTRUDA®), Merck's anti-PD-1 therapy, versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (aRCC) (NCT02811861; Abstract: #364).

Key Points: 
  • We look forward to engaging in critical scientific exchange to improve outcomes for these patients."
  • A network meta-analysis to assess the efficacy of lenvatinib plus pembrolizumab compared with other first-line treatment options for patients with aRCC will be shared in a poster session (Abstract: #482).
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • These abstracts will be made available via the ASCO website on Monday, January 22, 2024, at 5:00 PM EST (2:00 PM PST).

Eisai Furthers Oncology Research in Gastrointestinal Cancer Treatment with New Data at ASCO GI 2024

Retrieved on: 
Tuesday, January 16, 2024

NUTLEY, N.J., Jan. 16, 2024 /PRNewswire/ -- Eisai announced today the presentation of gastrointestinal cancer research during the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI24), which is taking place in-person in San Francisco, California and virtually from January 18-20.

Key Points: 
  • "We look forward to convening in San Francisco to share longer-term efficacy and safety results from the Phase 3 LEAP-002 trial with the scientific community at ASCO GI 2024.
  • Tasurgratinib, for which a marketing authorization application was submitted in Japan in December 2023, is an orally available selective TKI of FGFR1-3.
  • There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
  • These abstracts will be made available via the ASCO website on Tuesday, January 16, 2024, at 5:00 PM EST (2:00 PM PST).

Atossa Therapeutics Issues Letter to Shareholders

Retrieved on: 
Tuesday, January 9, 2024

SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:

Key Points: 
  • SEATTLE, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announces the issuance of the following Letter to Shareholders from Steven Quay, M.D., Ph.D., the Company’s President and Chief Executive Officer:
    2023 marked another year of significant progress for Atossa.
  • If you would like to learn more about the study, please visit www.atossatherapeutics.com to view a short video interview I conducted with Dr.
  • Adding to the issue is the fact that there are currently no approved treatments to reduce breast density.
  • On behalf of the board of directors, management, and employees of Atossa Therapeutics, we thank you for your investment and continued support of our Company.

Genprex Provides Business Update and Outlook for 2024

Retrieved on: 
Friday, January 5, 2024

AUSTIN, Texas, Jan. 5, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today provides a review of its 2023 achievements and a preview of plans for advancing its diabetes and oncology gene therapy programs in 2024.

Key Points: 
  • Our accomplishments in 2023, which also include process improvements in our manufacturing operations and securing new supplies of REQORSA, sets the foundation for a strong 2024."
  • Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Nanoparticle Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles.
  • In May, Genprex completed the Phase 1 portion of the Acclaim-1 clinical trial and reported encouraging results.
  • In October 2023, Genprex entered into a one-year extension to the August 2022 sponsored research agreement with the University of Pittsburgh.

Harvey J. Berger, M.D. Joins Kojin Therapeutics as Chairman, President, and Chief Executive Officer

Retrieved on: 
Wednesday, January 3, 2024

Kojin Therapeutics, Inc., a pioneer in cell-state and ferroptosis biology and cutting-edge drug discovery, today announced the appointment of Harvey J. Berger, M.D.

Key Points: 
  • Kojin Therapeutics, Inc., a pioneer in cell-state and ferroptosis biology and cutting-edge drug discovery, today announced the appointment of Harvey J. Berger, M.D.
  • as its new chairman, president, and chief executive officer.
  • He founded ARIAD Pharmaceuticals and led the company from a start-up to a fully integrated global oncology company.
  • Kojin co-founder Professor Stuart Schreiber stated, “We are thrilled to welcome Dr. Berger, a long-time colleague and collaborator, as Kojin’s new chief executive.

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

Retrieved on: 
Thursday, December 21, 2023

CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued

Key Points: 
  • CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued
    PARIS, December 21, 2023.
  • Sanofi is discontinuing the global clinical development program of tusamitamab ravtansine.
  • An Independent Data Monitoring Committee (IDMC) found that tusamitamab ravtansine as a monotherapy did not meet its dual primary endpoint of progression-free survival (PFS) compared to docetaxel.
  • “Our team is grateful to the patients, families and healthcare professionals involved in the tusamitamab ravtansine development program.

Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023

Retrieved on: 
Sunday, December 10, 2023

PALO ALTO, Calif., Dec. 10, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced the presentation of two preclinical posters at the 65th Annual Meeting of the American Society for Hematology (ASH 2023) for VIP943, for leukemias and myelodysplastic syndrome, and VIP924, for B-cell malignancies.

Key Points: 
  • “We are excited to share new preclinical data for VIP943 and VIP94 with our stakeholders,” said Ahmed Hamdy, M.D., Chief Executive Officer of Vincerx.
  • Poster #1435: Selectivity and Safety of VIP943: A novel CD123 Targeting Antibody-Drug Conjugate (ADC) Using a Proprietary Linker and Payload Class.
  • Objective: The poster outlines a series of assays used to characterize the preclinical properties of VIP943, including biochemistry, pharmacology, on-target selectivity and activity, safety, and toxicokinetics.
  • Complete blood counts (CBCs) show that VIP924 had minimal impact on the six elements of the CBC reported in these studies.

Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody

Retrieved on: 
Tuesday, December 5, 2023

PROVIDENCE, Rhode Island, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development and commercialization of scientifically compelling assets from research universities and medical centers, announced today that its Scientific Co-founder, Jack A. Elias, MD, co-authored new findings in the peer-reviewed journal Immunity that detail the mechanisms behind the role of chitinase 3-like-1 (CHI3L1) in the growth of triple negative breast cancer. The groundbreaking discoveries by a team led by Dr. William Muller at McGill University and in collaboration with Dr. Elias demonstrates that CHI3L1 stimulates neutrophil elaboration of NETs which block T cells from contacting and killing the breast cancer tumor. Additionally, the study provides further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in reversing this process and suppressing breast cancer tumor growth.

Key Points: 
  • Additionally, the study provides further evidence of the potential impact of Ocean’s anti-Chi3L1 antibody in reversing this process and suppressing breast cancer tumor growth.
  • This groundbreaking paper deepens the understanding of how CHI3L1 inhibits the body’s natural ability to fight breast cancer tumors.
  • Although these findings were defined in NSCLC, they have potential effectiveness in other EGFR-mutation driven cancers including Glioblastoma and Colon cancer.
  • Prior research has established that elevated Chi3L1 levels are associated with many cancers, including glioblastoma, and may be targeted therapeutically.